References
- De Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic
disease of the fetus and newborn. Vox Sang 2015; 109: 99-113
- Tiblad E, Kublickas M, Ajne G, Bui The Hung, Karlsson A, Ek S et
al.Procedure related complications and perinatal outcome after
intrauterine transfusions in red cell alloimmunization in Stockholm.
Fetal Diagn Ther 2011; 30:266-273
- Moise KJ. Management of rhesus alloimmunization in pregnancy. Obstetr
Gynecol 2008; 112: 164-176
- Urbaniak SJ. The scientific basis of antenatal prophylaxis. Br J
Obstetr Gynecol 1998; 105:11-18
- Crowther CA, Middleton P. Anti-D administration in pregnancy for
preventing rhesus alloimmunization. The Cochrane Library 2009
- Clausen FB. Lessons learned from the implementation of non-invasive
fetal RHD screening. Experts Review of Molecular Diagnostics
2018;5:423-431
- Davies J, Chant R, Simpson S, Powell R. Routine antenatal anti-D
prophylaxis: is the protection adequate? Transfus Med 2011; 21:
421-426
- White SW, Cheng JC, Penova-Veselinovic B, Wang C, White M, Ingleby B
et al. Single dose v two-dose antenatal anti-D prophylaxis: a
randomized controlled trial. Medical Journal of Australia 2019;
16:261-265
- Koelewijn JM, Haas de M, Vrijkotte TGM, van der Schoot CE, Bonsel GJ.
Risk factors for RhD immunisation despite antenatal and postnatal
anti-D prophylaxis. BJOG 2009; 116: 1307-1314.
- Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J et al.BCSH
for the use of anti-D immunoglobulin for the prevention of hemolytic
disease of the newborn. Transf Med 2014;24:8-20
- Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental
hemorrhage during pregnancy and after delivery. Vox Sang.
1986;51:117–121
- Tiblad E, Westgren M, Pasupathy D, Karlsson A, Wikman A. Consequences
of being RhD immunized during pregnancy and how to optimize new
prevention strategies. ACTA Obstetr Gynecol 2013; 92: 1079-1085
- MacKenzie IZ, Roseman F, Findlay J, Thompson K, Jackson E, Scott J, et
al. The kinetics of routine antenatal prophylactic intramuscular
injections of polyclonal anti-D imunoglobulin. BJOG. 2006;113:97–101.
- Pilgrim H, Lloyd-Jones M, Reese A. Routine antenatal anti-D
prophylaxis for RhD negative women; a systematic review and economic
evaluation. Health Technol Asses 2009;13:1-103
- Taune Wikman A, Tiblad E, Karlsson A, Olsson ML, Westgren M. Non
invasive single exon determination of fetal RHD in a routine screening
programme in early pregnancy. Obstetr Gyneol 2012; 120:227-234
- Graviditetsimmunisering ”Pregnancy immunisation”2015.https://www.sfog.se/media/275278/argrapp74_omsl_inledn_lr_f_r_oinloggade.pdf
- Austin E, Bates S, de Silva M, Howarth D, Lubenko A, Rowley M, Scott
M, Thomas E, White J, Williams M. Guidelines for the estimation of
fetomaternal haemorrhage. Working party of the British Committee of
Standards in Haematology, Transfusion Task
Force.https://b-s-h.org.uk/media/15705/transfusion-austin-the-estimation-of-fetomaternal-haemorrhage.pdf
- Sebring ES, Polesky HS. Fetomaternal hemorrhage; incidence risk
factors, time of occurrence and clinical effects. Transfusion 1990;
30:344-357.
- Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin
prophylaxis: an analysis of the reasons for such failures. Transfus
Med Rev. 1987;1:101–112.
- Lubusky M, Simetka O, Studnickova M, prochazka M, Ordeltova M,
Vomackova K. Fetomaternal hemorrhage in normal vaginal delivery and in
delivery by cesarian section. Transfusion 2012; 52:1977-1982
- World health Organisation. Prevention of Rh sensitization. Geneva;
W.H.O Technical Report Series 468,1971:29.
- Medical Research Council Controlled trial of various anti-D dosages in
suppression of rhesus sensitisation following pregnancy. Report to the
Medical Research Council by the working party on the use of anti-D
immunoglobulin for the prevention of the isoimmunization of Rh
negative women during pregnancy. Br Med J 1974;ii75-80.
- https://www.fass.se/LIF/product?userType=0&nplId=20021115000215&docType=6&scrollPosition=785.3333129882812#pharmacodynamic
- Tiblad E, Wikman A, Rane A, Jansson Y, Westgren M. Pharmacokinetics of
250 g anti-D in the third trimester of pregnancy: an observational
study. Acta Obstetr Gynecol 2012; 91: 587-592
Table 1 Characteristics of included women n=39